An update on pharmacotherapies and emerging therapeutic approaches for geographic atrophy.
INTRODUCTION Geographic atrophy (GA) secondary to age-related macular degeneration is a leading cause of irreversible vision loss. The 2023 FDA approvals of pegcetacoplan and avacincaptad pegol were a milestone, but modest anatomic benefit without demonstrated prespecified functional benefit, increased neovascular conv...